Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 12 | 2024 | 70 | 2.610 |
Why?
|
| Breast Neoplasms | 17 | 2024 | 2480 | 2.000 |
Why?
|
| Estrogen Receptor alpha | 6 | 2023 | 444 | 1.040 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 717 | 0.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 254 | 0.770 |
Why?
|
| Endocytosis | 3 | 2011 | 124 | 0.730 |
Why?
|
| Neoplasms | 6 | 2024 | 2752 | 0.680 |
Why?
|
| Receptors, Estrogen | 5 | 2024 | 788 | 0.680 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1677 | 0.650 |
Why?
|
| Gene Fusion | 1 | 2018 | 55 | 0.610 |
Why?
|
| Receptors, Interleukin-5 | 2 | 2008 | 4 | 0.600 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 217 | 0.570 |
Why?
|
| Proteomics | 10 | 2024 | 478 | 0.460 |
Why?
|
| Signal Transduction | 8 | 2021 | 4514 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2024 | 37 | 0.430 |
Why?
|
| Lysine | 2 | 2011 | 201 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2024 | 54 | 0.430 |
Why?
|
| Ubiquitination | 2 | 2021 | 174 | 0.410 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2011 | 1 | 0.390 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 14 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 354 | 0.360 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 136 | 0.350 |
Why?
|
| Eosinophils | 2 | 2008 | 121 | 0.350 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 217 | 0.340 |
Why?
|
| Precision Medicine | 2 | 2023 | 311 | 0.330 |
Why?
|
| Transferrin | 1 | 2008 | 51 | 0.310 |
Why?
|
| src-Family Kinases | 2 | 2016 | 83 | 0.300 |
Why?
|
| Mutation | 8 | 2024 | 5786 | 0.290 |
Why?
|
| Janus Kinases | 1 | 2007 | 31 | 0.280 |
Why?
|
| Ubiquitin | 1 | 2007 | 142 | 0.260 |
Why?
|
| Humans | 34 | 2024 | 122409 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 2 | 2024 | 327 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 81 | 0.240 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 12 | 0.240 |
Why?
|
| Down-Regulation | 1 | 2007 | 701 | 0.230 |
Why?
|
| Benzamides | 1 | 2024 | 107 | 0.220 |
Why?
|
| Neurofibromin 1 | 2 | 2023 | 42 | 0.220 |
Why?
|
| Female | 22 | 2024 | 64937 | 0.220 |
Why?
|
| Paclitaxel | 1 | 2024 | 122 | 0.220 |
Why?
|
| Nitriles | 1 | 2024 | 145 | 0.220 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 549 | 0.210 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 99 | 0.200 |
Why?
|
| Machine Learning | 1 | 2024 | 212 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 62 | 0.200 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 325 | 0.200 |
Why?
|
| Proteome | 1 | 2023 | 234 | 0.200 |
Why?
|
| Metformin | 1 | 2023 | 135 | 0.190 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 3301 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 408 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1674 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2315 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1250 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 194 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1889 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 103 | 0.170 |
Why?
|
| Genomics | 4 | 2023 | 1475 | 0.160 |
Why?
|
| Software | 1 | 2024 | 672 | 0.160 |
Why?
|
| Claudins | 1 | 2018 | 29 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2024 | 1160 | 0.160 |
Why?
|
| Mitosis | 1 | 2018 | 239 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1431 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2020 | 333 | 0.150 |
Why?
|
| MutL Proteins | 1 | 2017 | 19 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 33 | 0.150 |
Why?
|
| Phosphorylation | 4 | 2023 | 1615 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 271 | 0.140 |
Why?
|
| Prognosis | 2 | 2023 | 4492 | 0.140 |
Why?
|
| Protein Binding | 3 | 2021 | 1740 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 645 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 1076 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2018 | 416 | 0.130 |
Why?
|
| Mammary Glands, Human | 1 | 2016 | 80 | 0.120 |
Why?
|
| Cell Movement | 1 | 2018 | 839 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 874 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 525 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2021 | 697 | 0.120 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 222 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 943 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1387 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2024 | 662 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1622 | 0.090 |
Why?
|
| Endosomes | 1 | 2011 | 67 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 369 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2011 | 746 | 0.080 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 5 | 0.080 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2008 | 6 | 0.080 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 13 | 0.080 |
Why?
|
| Clathrin | 1 | 2008 | 24 | 0.080 |
Why?
|
| Cholera Toxin | 1 | 2008 | 45 | 0.080 |
Why?
|
| Interleukin-5 | 1 | 2008 | 44 | 0.080 |
Why?
|
| Animals | 8 | 2024 | 33891 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2023 | 619 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 156 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12036 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 18777 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2007 | 14 | 0.070 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 59 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2021 | 282 | 0.070 |
Why?
|
| Protein Kinases | 2 | 2020 | 331 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2832 | 0.070 |
Why?
|
| Apoptosis | 2 | 2024 | 1792 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2008 | 459 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 291 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6302 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 810 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 758 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 280 | 0.060 |
Why?
|
| Mice | 5 | 2024 | 17637 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 713 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 2 | 2020 | 497 | 0.060 |
Why?
|
| Middle Aged | 5 | 2024 | 25586 | 0.060 |
Why?
|
| Protein Interaction Maps | 1 | 2024 | 77 | 0.060 |
Why?
|
| Phosphopeptides | 1 | 2023 | 27 | 0.060 |
Why?
|
| Adult | 5 | 2024 | 28743 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 581 | 0.060 |
Why?
|
| Knowledge Bases | 1 | 2023 | 36 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 213 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 156 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 83 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 107 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 223 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 227 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2023 | 122 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 78 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 114 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 354 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 208 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 795 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2021 | 19 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1439 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 142 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 394 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2787 | 0.050 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2021 | 36 | 0.050 |
Why?
|
| Acetylation | 1 | 2021 | 166 | 0.050 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 3076 | 0.050 |
Why?
|
| Peptides | 1 | 2024 | 801 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 608 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 76 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 4648 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 493 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 386 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 36 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1076 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 198 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 103 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 352 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1082 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 136 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 38 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 122 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 24 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 69 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 572 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 65 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2020 | 363 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 184 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1023 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 351 | 0.040 |
Why?
|
| DNA Damage | 1 | 2020 | 517 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 396 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 678 | 0.040 |
Why?
|
| DNA Repair | 1 | 2020 | 585 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 75 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 675 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 375 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2001 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 17 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 24 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 1994 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 483 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 345 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 90 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 74 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 112 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 144 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 906 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1527 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 328 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2016 | 401 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 343 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 287 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2018 | 814 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4310 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 638 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1704 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 5970 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1283 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2008 | 37 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 43 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 68 | 0.020 |
Why?
|
| Turner Syndrome | 1 | 2008 | 47 | 0.020 |
Why?
|
| Male | 3 | 2021 | 59575 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 338 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8805 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 348 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 793 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 2532 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 13837 | 0.010 |
Why?
|